Small-cap pharma stock rallies 178% in 2026, extends winning run into fifth year; key factors behind rally
· LiveMint Markets
Cupid, a consumer wellness company, saw its shares surge 178% in 2026, driven by growing orders and expansion plans. This follows a 584% surge in 2025. The stock's recent rally has enhanced its market cap to ₹25,000 crore, benefiting retail investors significantly.
The analysis
Because the driver here is macro rather than company-specific, the read-through is to index-level positioning rather than to any single name — correlations tend to rise when the whole market faces the same signal.
Market context
- This is a market-wide development — its reach goes beyond any single stock.
- Sector exposure: Pharma & Healthcare, Consumer Durables.
- The immediate tone of coverage reads positive.
In this story
Related coverage
Tech start-up Eloelo launches Dolphin AI for video creation
Stock Market Crash LIVE: Sensex Tanks Over 1,200 Points, Nifty 50 Below 22,200; ITC, JSW Steel, IndiGo Among Top Losers
INR vs USD: Rupee near 97/dollar; how TCS, Sun Pharma, Tata Steel, SRF may gain from weaker currency? Experts explain
Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price
Titan reports 25% revenue growth in Q2FY27, jewellery sales up 21%